Skip to main content
Premium Trial:

Request an Annual Quote

Grifols RHD Genotyping Test Gets CE Mark

NEW YORK (360Dx) – Grifols today announced CE marking for its ID RHD XT diagnostic test for RHD genotyping.

The kit, the firm said, is designed to be used on the same platform as its ID Core XT and ID HPA XT molecular typing solutions. The reliability, speed, and accuracy of the new test also matches those of ID Core XT and ID HPA XT, and enables immunochematologists to obtain results within four hours of DNA extraction.

Grifols said that RHD genotyping has been recommended by the Work Group on RHD Genotyping convened by the AABB and College of American Pathologists, and can reduce unnecessary administration of RhIG in pregnant women. It also can reduce unnecessary transfusion of RhD-negative blood cells to recipients with a serologic weak D phenotype.

ID RHD XT includes the variants specified in these recommendations, Grifols said. The test is manufactured by Grifols company Progenika.